Edward G. Carr's most recent trade in Dianthus Therapeutics Inc was a trade of 23,465 Common Stock done at an average price of $81.8 . Disclosure was reported to the exchange on March 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 81.75 per share. | 12 Mar 2026 | 23,465 | 4,365 | - | 81.8 | 1,918,264 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 17,500 | 42,500 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.07 per share. | 12 Mar 2026 | 17,500 | 33,682 | - | 22.1 | 386,225 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 16,182 | 63,818 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 12 Mar 2026 | 16,182 | 16,182 | - | 17.9 | 289,334 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 80.71 per share. | 12 Mar 2026 | 15,852 | 27,830 | - | 80.7 | 1,279,415 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.77 per share. | 12 Mar 2026 | 10,000 | 43,682 | - | 21.8 | 217,700 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 10,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 82.66 per share. | 12 Mar 2026 | 3,865 | 500 | - | 82.7 | 319,481 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 85.53 per share. | 12 Mar 2026 | 300 | 0 | - | 85.5 | 25,659 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 83.38 per share. | 12 Mar 2026 | 200 | 300 | - | 83.4 | 16,676 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Abeona Therapeutics Inc | Edward G. Carr | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2021 | 476,000 | 476,000 | - | - | Stock Option (right to buy) | |
| Abeona Therapeutics Inc | Edward G. Carr | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2021 | 238,000 | 429,291 (0%) | 0% | 0 | Common stock | |
| Abeona Therapeutics Inc | Edward G. Carr | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 1.80 per share. | 31 Mar 2021 | 35,000 | 191,291 (0%) | 0% | 1.8 | 62,846 | Common stock |
| Abeona Therapeutics Inc | Edward G. Carr | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 1.85 per share. | 31 Mar 2021 | 20,445 | 226,291 (0%) | 0% | 1.9 | 37,866 | Common stock |